services-cross

With a portfolio of more than 450 clinical studies performed both in healthy volunteers and patients, CROss Alliance® team has built “on the field” a deep knowledge of several clinical areas. An overview of our capabilities in these specific areas is provided here below, but for any additional request, do not hesitate to get in touch with us.

We constantly try to expand this section, so do not forget to come back and check for further updates.

More than 70 different molecules have been tested by CROss Alliance® in bioequivalence (BE) and bioavailability (BA) studies carried out in healthy volunteers for the clinical development of both ethical or generic drugs. In these studies small & high molecular weight compounds, endogenous substances, pro-drugs and locally active drugs were investigated.

Thanks to the in house availability of senior biostatisticians and pharmacokinetic experts, CROSS’ team is able to advice its Clients in the selection of the most suitable BE/BA study design (parallel, cross over, replicated, two-stage) for each molecule considering the specific regulatory framework (EMA / FDA) and maximising the possibility of success.

CROss Alliance clinical team has deep expertise in most administration routes: intravenous (bolus or infusion), subcutaneous, intramuscular, oral, epicutaneous, vaginal and rectal which do not represent an obstacle neither for the performance of the studies nor for the recruiting of subjects. Moreover, all relevant pharmaceutical forms have been tested at CROSS’ clinical unit: solutions, suspensions, capsules, tablets (ODT, IR, MR), granules, films, creams, gels, transdermal plasters or patches and suppositories.

Molecules investigated in clinical BE/BA studies

Acarbose Doxycicline Manidipine Prazepam
Acyclovir Emedastine Meclofenamate Prochlorperazine
Alendronate EPA / DHA Melatonin Propafenone
Amoxycilline Fentanyl Meloxicam Propionyl-L-Carnitine
Benserazide Filgrastim Mesalazine Riluzole
Bosentan Finasteride Metformin SAMe
Budesonide Flurbiprofen Methylprednisolone Sildenafil
CaCO3 Folic, 5-MTHF Metoprolol Tacrolimus
Codeine Fosfomycin Midazolam Ticlopidine
Calcitriol FSH NAC Tobramycin
Canrenoate Gabapentin Naproxen Tolmetin
Clodronate Glibenclamide Netupitant Tramadol
Clozapine Ketoconazole Nimesulide Trazodone
Cysteamine Ketoprofen Octreotide Triflusal
Diazepam Ibuprofen Omeprazole Tyroxine
Diclofenac Levodopa Oxibutinin UDCA
Diltiazem Levodropropizine Palonosetron Xipamide
Desmopressin Loperamide Paracetamol

The long QT syndrome is a disease of myocardial ion channels that manifests clinically as recurrent syncope or cardiac arrest due to malignant ventricular arrhythmias. Health Authorities issued a specific guideline while protocols satisfying the regulatory demand have been designed.

CROss Alliance® has acquired a specific expertise in QTc prolongation studies performed in HV and in cooperation with ERT (leading provider for cardiac safety), is able to offer a full service QTc prolongation study compliant with the different US and EU regulatory requests.

To learn more about CROSS & ERT cooperation:

 

References:

1) Rosignoli MT, Di Loreto G, Dionisio P. “Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study”. Clin Drug Investing. 2010;30(1):5-14.

Acquired expertise in HV and/or patients

1. PK in Cerebral Spinal Fluid: When it is unknown whether a drug penetrates the CNS, determination of its presence into the CSF helps in establishing valuable PK/PD relationships. Studies on this nature are difficult to perform for ethical and technical reasons as it is not feasible to collect more than a few samples per subject. Therefore, population based pharmacokinetic approaches describing serum vs. CSF concentrations of the drug, are required, (1).

2. Positron Emission Tomography: A validated approach to obtain data of a NCE at the earlier stage of development is the microdosing concept which involves administration of a sub-pharmacological dose of the test compound to humans. The non invasive nuclear imaging PET in conjunction with 11C or 18F labelling is the method of choice for investigating the kinetic profile of a NCE both in blood and tissues of HV vs. patients administered the labelled drug, (2).

3. Low Resolution Brain Electromagnetic Tomography: With the aim of understanding whether a drug works within the brain, EEG-tomography (LORETA), by combining the high time resolution of the EEG with a source localization method that permits a 3-Dimensional tomography of the brain electrical activity, becomes the technique of choice. Different CNS drugs affect brain structures differently which may be visualized by horizontal, sagittal and coronal slices through the brain regions showing the most significant findings after the drug vs. placebo or by surface-rendered statistical parametric maps, (3).

4. Neuropathic Pain: Phase II studies aimed to treat neuropathic pain have been carried out on NCEs (MAO-B inhibitors and nootropic drugs) administered, according to placebo controlled designs, to patients with neuropathic pain and in HIV patients suffering from antiretroviral treatment induced neuropathy.

References

1) Valle M, Barbanoj MJ, Donner A, Izquierdo I, Herranz U, Klein N, Eichler HG, Muller M, Brunner M. “Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers”. Eur J Clin Pharmacol. (2005), 61, 103-11.

2) Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger R, Hofmann A, Joukhadar C, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado ME, Lods N, Dudczak R, Auff E, Kletter K, Muller M. “A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease”. Clin Pharmacol 2006 80(3):216-27.

3) Saletu B, Anderer P, Wolzt M, Nosiska D, Assandri A, Noseda E, Nannipieri F, Saletu-Zyhlarz GM “Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study on the Pharmaco-dynamics of ABIO-08/01, a New CNS Drug with Potential Anxiolytic Activity. 2. EEG-Tomography Findings Based on LORETA (Low-Resolution Brain Electromagnetic Tomography)” Neuropsychobiology. 2009 Apr 10;59(2):110-122.

Acquired expertise in healthy volunteers and/or patients

1. Basic PK studies: The release of a test drug from a topical formulation, its percutaneous absorption, systemic bioavailability and safety are determined in HV and patients administered by single/multiple doses of gels, creams, ointments, foams, plasters, patches, films, etc. The relationships existing between the measured kinetic parameters and the site of application, the skin properties, the environmental conditions, and the patch adhesiveness, can be investigated (1-2).

2. Safety studies: With the aim of assessing the local tolerability & sensitisation potential, dermal irritation, photo-toxicity and photo-sensitisation are performed following protocols as for the relevant guidelines (4).

3. Topical corticosteroids (Cs): Topical Cs exerts vasoconstriction on the peripheral dermal vessels causing skin blanching. The magnitude of this effect is measured using colorimetric techniques and it is accepted as a surrogate variable BA when a Cs-product is applied to the skin. It is then possible to establish the BE between 2 topical products containing the same quali-quantitative composition in Cs and excipients.

4. Percutaneous absorption: In vivo PK data on the penetration into sub-epidermal layers of a test drug is possible by employing microdialysis and 2-D ultrasound. The technique is based on diffusion of analytes from the extra-cellular space through a semi-permeable membrane. The process is accomplished in vivo by a probe perfused with a physiological solution at low flow rate. Once probe is implanted into the tissue, substances diffuse from the extra-cellular fluid into the perfusion medium, which is collected and analysed (3).

5. Skin Biopsy: Androgenetic alopecia depends both on genetic predisposition and on the local presence of androgen dihydrotestosterone (DHT) which is formed from testosterone (T) by a 5-alpha reductase. Patients with androgen insensitivity syndrome and type-2 5-alpha reductase deficiency, show activation of follicular androgen receptors by DHT. In males undergoing a pharmacological treatment with a test drug T and DHT concentrations can be concurrently analysed in scalp biopsies and serum (5-6).

6. Efficacy trials: Study protocols designed to investigate the efficacy of a test drug in patient populations with different dermatological pathologies (acne, alopecia, herpes, psoriasis, atopic dermatitis) have been developed by Cross and can be tailored for other test molecules.

References

(1) Brunner M, Davies D, Martin W, Leuratti C, Lackner E, Müller M. “A new topical formulation enhances relative diclofenac bioavailability in healthy male subjects.” Br J Clin Pharmacol. 2011 Jan 17. PubMed

(2) Monti D, Herranz U, Dal Bo L, Subissi A. “Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.” J Eur Acad Dermatol Venereol. 2013 Feb. PubMed

(3) Burian A, Frangione V, Rovati S, Mautone G, Leuratti C, Vaccani A, Crevenna R, Keilani M, Burian B, Brunner M, Zeitlinger M. “An exploratory microdialysis study investigating the effect of repeated application of a diclofenac epolamine medicated plaster on prostaglandin concentrations in skeletal muscle after standardized physical exercise.” Br J Clin Pharmacol. 2013 Apr 1. PubMed

(4) Di Stefano A F D, Radicioni M M, Vele A, Mancarella Eberhardt A, Caccia G, Focanti F, Salvatori E, “Tolerability and hydrating effects of an anti-aging gynaecological collagen cream in women in menopause” OJOG. 2014 Feb; Vol.4, No.3. OJOG

(5) Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R, “A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.” Int J Clin Pharmacol Ther. 2014 Oct; 52(10):842-9. PubMed

(6) Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R, “Effect of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia”. International Journal of Clinical Pharmacology and Therapeutics. 2016; 54:19-27. PubMed

Acquired expertise in HV and/or patients

1. Effect of gastric pH on drug absorption: pump inhibitors administration allows increasing gastric juice pH that can be continuously recorded by nasal-gastric probes while the rate and extent of the systemic absorption of a test drug is concurrently measured.

2. Gastrolesivity evaluation: NSAIDs alone or in combination administered at high dosages according to multiple regimens induce gastric damages (erosions, submucosal hemorrhages, ulcers) that can be easily monitored and scored by gastric endoscopy, (1).

3. Small intestine damages: the most recent Video Capsule Endoscopy with the PillCam™, is a valuable tool to investigate, throughout the whole gastro intestinal tract but particularly in the non endoscopically accessible small intestine, treatment related events.

4. Pharmaco-scintigraphy: is a technique used to evaluate the  in vivo performance of new oral delivery systems, i.e. capsules, tablets, pellets, enemas. When these data are compared with the PK of the drug it is possible to relate the drug absorption to the formulation fate in the GI tract (location, transit, disintegration, persistence). Complex forms, like enteric-coated tablets, can be labelled by the addition of a non-radioactive tracer as 152Sm2O3 followed by neutron activation of the final product, (2, 3).

References:

1) Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology. 2003 Mar;124(3):600-7.

2) Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R, Eichler HG, Muller M. “Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation”. Aliment Pharmacol Ther. (2003). 17, 395-402.

3) Brunner M, Ziegler S, Di Stefano AF, Dehghanyar P, Kletter K, Tschurlovits M, Villa R, Bozzella R, Celasco G, Moro L, Rusca A, Dudczak R, Muller M. “Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation”. Br J Clin Pharmacol. (2005) ,61, 31-38.